Temporal changes in IgG. by Hiromi Yamaguchi (2396248)

Subjects:

IgG periodicity. by Hiromi Yamaguchi (2396248)

Subjects:

SWSs measured for cell-laden gels with 5 mg/ml Matrigel and 1 mg/ml (M5C1), 2 mg/ml (M5C2), and 3 mg/ml (M5C3) collagen type I. by Shao-Lun Lu (12360135)

THC reversed PCP-induced decrease in dopamine neuron population activity in the VTA. by Alexandre Seillier (8566116)

The monoterpene 1,8-cineole decreased parasitemia levels in vitro. by Edgleyson C. dos Santos (12536575)

JBPOS0101 decreased Amyloid Beta (Aβ) aggregates in the cortex and hippocampal regions in 5xFAD mouse brains. by Jihoon Jeong (4852690)

GXM decreases the trans-endothelial electrical resistance (TEER) and transmigration of <i>C</i>. <i>neoformans</i> through HBECs in a blood brain barrier (BBB) model. by Hiu Ham Lee (15374677)

Y-27632 collaborated with BA to attenuate the increase in the integrity and decrease in the permeability of epithelial barrier injury induced by LPS in Caco2 monolayers. by Luqiong Liu (11537092)

Y-27632 synergized with BA to alleviate the decrease in the expression of and abnormal localization of ZO-1 and Occludin in LPS-induced Caco2 cells. by Luqiong Liu (11537092)

Effect of H5 (20 mg/kg, p.o.) on paw edema induced by histamine in mice. by Maria Alice Miranda Bezerra Medeiros (11752002)

Effect of H5 (20 and 40 mg/kg, p.o.) and indomethacin (20 mg/kg, i.p.) on paw edema induced by carrageenan in mice. by Maria Alice Miranda Bezerra Medeiros (11752002)

Adverse events in low-dose naltrexone arm. by Judith I. Tsui (5983160)

Subjects:

CONSORT flow diagram. by Judith I. Tsui (5983160)

Subjects:

Adverse events in placebo arm. by Judith I. Tsui (5983160)

Subjects:

Medication tolerability, discontinuations, adherence over the 8-week study period. by Judith I. Tsui (5983160)

Subjects:

Adverse events in gabapentin arm. by Judith I. Tsui (5983160)

Subjects:

Medication satisfaction over 8-week study medication period. by Judith I. Tsui (5983160)

Subjects:

Main results: Changes in primary and secondary outcomes from baseline to 8 weeks in the PETER PAIN trial. by Judith I. Tsui (5983160)

Subjects:

Baseline characteristics of PETER PAIN study participants: People with HIV, chronic pain, and heavy alcohol use (n = 45). by Judith I. Tsui (5983160)

Subjects:

Percent of land use during the BASE20 and HG-2 (MRISSP5) scenario along with corresponding mean annual TN concentration values (mg/L) across all intake locations. by Elly T. Gay (21170097)